In a Drug Development & Delivery special report, Quotient Sciences experts explained techniques that are being used to identify the most viable bioavailability and solubility enhancement strategies for modern drug candidates.
Quotient Sciences’ contribution focused on the challenges associated with poorly soluble compounds and the limitations of relying solely on predictive in vitro or preclinical models when selecting formulation strategies. Quotient Sciences’ integrated approach to formulation selection combines enabling technologies, like particle size reduction and amorphous solid dispersions, with early human data to guide development pathways.
At the same time, the article reinforced a key theme: no single technology or model can address bioavailability and solubility challenges in isolation.
Instead, the most effective strategies emerge from combining computational insight with experimentally derived, clinically relevant data—an approach that aligns closely with Quotient Sciences’ Translational Pharmaceutics® platform. By evaluating formulation performance in humans earlier in development, Quotient Sciences helps reduce the risk of late‑stage formulation failure and unnecessary investment in sub‑optimal approaches.
The full special feature, “Bioavailability & Solubility: Experimental Techniques Combined With Computational Decision‑Making Rapidly Identify the Most Viable Enhancement Pathway,” is now available to read in full on the Drug Development & Delivery website with contributions from Paloma Benito Gallo, Senior Modelling and Simulations Research Fellow; Jane McGuffog, Director, Modelling and Simulation; and Dr. Andrew Lewis, Chief Scientific Officer.